Drug intelligence / Profile preview

B003

Development stage: Phase 1
Lead developer: Shanghai Pharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

B003 is a recombinant anti-HER2 humanized monoclonal antibody conjugate developed by Shanghai Pharmaceuticals Holding Co., Ltd. It is currently in a Phase I clinical trial to assess its safety, tolerability, and pharmacokinetics in patients with HER2-positive recurrent or metastatic breast cancer. The drug is designed to specifically target the Human epidermal growth factor receptor 2 (HER2) protein, which is often overexpressed in certain types of cancer.

Other names: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on B003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B003.

Explore the full profile